150 related articles for article (PubMed ID: 12570696)
1. Surrogate markers as a guide to evaluate response to antiretroviral therapy.
De Milito A; Titanji K; Zazzi M
Curr Med Chem; 2003 Mar; 10(5):349-65. PubMed ID: 12570696
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
4. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.
Sánchez-Ramón S; Bellón JM; Resino S; Cantó-Nogués C; Gurbindo D; Ramos JT; Muñoz-Fernández MA
Pediatrics; 2003 Feb; 111(2):E168-75. PubMed ID: 12563091
[TBL] [Abstract][Full Text] [Related]
5. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
[TBL] [Abstract][Full Text] [Related]
6. [Surrogate endpoints in clinical studies exemplified by HIV infection].
Furrer H
Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1079-88. PubMed ID: 9691341
[TBL] [Abstract][Full Text] [Related]
7. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
9. Discordant responses to cART in HIV-1 patients in the era of high potency antiretroviral drugs: clinical evaluation, classification, management prospects.
Cenderello G; De Maria A
Expert Rev Anti Infect Ther; 2016; 14(1):29-40. PubMed ID: 26513236
[TBL] [Abstract][Full Text] [Related]
10. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
Ann Intern Med; 2002 Sep; 137(5 Pt 2):381-433. PubMed ID: 12617573
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory effects of antiretroviral chemotherapy.
Schooley RT
J Biol Regul Homeost Agents; 1995; 9(3):110-3. PubMed ID: 8782019
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 dynamics in vivo: implications for therapy.
Simon V; Ho DD
Nat Rev Microbiol; 2003 Dec; 1(3):181-90. PubMed ID: 15035022
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects.
De Milito A; Aleman S; Marenzi R; Sonnerborg A; Fuchs D; Zazzi M; Chiodi F
Clin Exp Immunol; 2002 Mar; 127(3):486-94. PubMed ID: 11966765
[TBL] [Abstract][Full Text] [Related]
16. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
17. Surrogate markers for assessing treatment response in HIV disease.
Rathbun RC
Ann Pharmacother; 1993 Apr; 27(4):450-5. PubMed ID: 8097416
[TBL] [Abstract][Full Text] [Related]
18. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
Chang LW; Harris J; Humphreys E
Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
[TBL] [Abstract][Full Text] [Related]
19. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
20. Immune activation in patients infected with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy.
Almeida CA; Price P; French MA
AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1351-5. PubMed ID: 12487806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
